Safe Starts with Sensors: Pharmacists' Role in CGM Use

Emily Eddy ***PharmD, CDCES, BC-ADM, BCACP***
Associate Professor of Pharmacy Practice
Ohio Northern University

Brittany Long ***PharmD, BCACP, CTTS***
Associate Professor of Pharmacy Practice
Ohio Northern University

Pharmacy Forward: Advancing Practice for a Healthier Tomorrow!

OPA Annual Conference & Trade Show April 9-11, 2026

OHIO PHARMACISTS ASSOCIATION

Disclosure Statement

- Emily Eddy and Brittany Long have no relevant financial relationship(s) with ineligible companies to disclose.

and

- None of the planners for this activity have relevant financial relationships with ineligible companies to disclose.

Abbreviated Learning Objectives

At the completion of this activity, the participant will be able to:

1. Describe the currently available continuous glucose monitoring (CGM) systems and their FDA-approved indications

1. Identify potential safety concerns and limitations associated with CGM use

1. Evaluate clinical scenarios in which pharmacists can promote safe and effective use of CGM devices

1. Apply strategies to integrate CGM into pharmacy practice workflows while ensuring patient safety, appropriate referral, and coordination of care

Introduction to CGMs

History of Glucose Monitoring

1970s

Home Testing

Glucometers and test strips come to market

1999

First CGM Approved

MiniMed Professional CGM receives FDA approval

2004

First Home RT CGM approved

The Medtronic Guardian Real-Time (RT) CGM system (3-day) receives approval

2007

Expanded CGM Wear Time

Dexcom receives approval for the STS 7 (7-day)

2008

Expanded CGM Wear Time

Abbott receives approval for Freestyle Navigator (5-day)

2012

Expansion of Wireless Transmission

Dexcom G4 CGM (7-day) allowed for up to 20 feet transmission distance

Bender C, et al. Diabetology. 2025.
ConnectedinMotion [Internet]. 2023.
Afon Technology [Internet]. 2024.

History of Glucose Monitoring

2014

2015

Expanded Patient Population

Dexcom G4 Platinum received FDA approval for use in pediatric patients (2-17 yrs)

2017

First CGM With Monitoring Directly to Smartphone

Dexcom G5 Mobile CGM receives FDA approval for "direct-to-smartphone" monitoring

2018

Factory Calibration

Abbott Freestyle Libre CGM approved as the first CGM with factory calibration, removing the need for daily patient calibration

Implantable CGM

The first implantable CGM, the Eversense CGM, receives FDA approval

Integrated CGM Technology

The Dexcom G6 is the first approved CGM for integration to certain compatible AIDs

2024

First OTC CGM Approved

The Abbott Stelo OTC CGM is approved for adults who do not take insulin

Beyond…

What is next!?

Longer use of implantable CGM, fully internally contained sensors, ketone/lactate/stress hormone monitoring…..

Abbott [Press Release]. 2017.
AJMC Staff. AJMC [Press Release]. 2015. ; Bender C, et al. Diabetology. 2025.
Brown A. diaTribeLearn [Internet]. 2021. ; FDA [Press Release]. 2018.

Introduction to CGMs





Image From: Soni A, et al. Arch Dis Child Educ Pract Ed. 2022.

Types of CGMs



BGM

Blood Glucose Meter

Single, snapshot reading

110 Glucose reading

CGM

Intermittent-Scan CGM (Class III)

User must physically scan sensor to see readings/trends

110 Glucose reading

↓ Trend arrows

RT-CGM CGM

Real-Time CGM (Class III)

Alerts automatically warn users of impending highs/lows

110 Glucose reading

↓ ↓ Trend arrows

Proactive alerts

iCGM RT-CGM CGM

Integrated CGM (Class II)

Must meet rigorous performance requirements

110 Glucose reading

↓ ↓ Trend arrows

Proactive alerts

Interoperability

FDA Required performance benchmarks

Image From: https://provider.dexcom.com/dexcom-cgm

Why CGMs?

Individual Experience

Increased satisfaction

Better individual experience

Reported behavioral changes

Reduced Complications

Diabetic ketoacidosis (DKA)

Severe hypoglycemia

Diabetes-related coma

Hospitalization

Improved Outcomes

Glycemic outcomes

Better (lower) A1C levels

Healthcare Experience

Use of healthcare resources (emergency visits for hypoglycemia)

Potential Lower Cost

Prahalad P et al. J Clin Endocrinol Metab 2022. ; Tanenbaum ML et al. Diabet Med 2021.
Aronson R et al. Diabetes Obes Metab 2025. ; Vakharia M et al. Pediatr Qual Saf 2025.
7. Diabetes Technology: Standards of Care in Diabetes—2026. ;
Aleppo G et al Diabetes Care 2021. ; Addala A et al Pediatr Diabetes 2020.

What Does the ADA Say?

7.8	7.15	7.16	7.17	7.18
Consider **early initiation** of CGM depending on a person's or caregiver's needs and preferences	**CGM use is recommended at diabetes onset and thereafter** for anyone with diabetes on **insulin**, **hypoglycemia-causing non-insulin therapies**, or **any diabetes treatment where CGM helps in management**. The specific CGM device and method for use should be made based on the individual's circumstances, preferences, and needs.	In people **with diabetes on insulin** therapy, **CGM devices** should be used as close to **daily** as possible **for maximal benefit**. People with diabetes **should have uninterrupted access to their supplies** to minimize gaps in CGM.	During **pregnancy** for individuals with **type 1 diabetes**, **CGM** can help **achieve glycemic and A1C goals** and may be beneficial for other types of diabetes in pregnancy.	In circumstances **when consistent use** of CGM **is not feasible**, consider **periodic use of personal or professional CGM** to adjust medication and/or lifestyle.

7. Diabetes Technology: Standards of Care in Diabetes—

Currently Approved Prescription CGM Products

Prescription (Rx) CGMs

- Dexcom
  - Dexcom G6
  - Dexcom G6 Pro
  - Dexcom G7
  - **Dexcom G7 15 Day**
- Abbott
  - Freestyle Libre 2*
  - Freestyle Libre 3
  - Freestyle Libre 2 Plus
  - **Freestyle Libre 3 Plus**
- Senseonics Holdings
  - Eversense 365#
- Use with MiniMed 780G System
  - Guardian 4 Sensor (7 day - Medtronic)
  - Simplera Sync (6 day - Medtronic)
  - Instinct Sensor (15 day - Abbott)

** = intermittent CGM*

 # = implantable

ADCES. danatech Diabetes Technology. 2024.
Dexcom [Internet]. 2026.

Prescription CGMs: Let's Focus In

G7 15 Day (December 2025)

FreeStyle 3 Plus (September 2024)

G7 15 Day by Dexcom

G7 15 Day CGM

- For patients ≥ 18 years for managing DMT1, DMT2, or GDM
- Provides trends, summaries, reactions, readings, alerts, etc.
- Log meals, activities, medication, fasting, notes
  - Photo capabilities ; “Smart Food” log
- Connects numerous platforms, apps, devices
- RCT: Patients with DMT1/DMT2 wore CGM ~15 days
  - 4 Clinic visits → glucose analyzer readings paired to CGM data
  - Overall MARD = 8.0%
  - 94.3% of values within 20% of comparator values

Images from:
https://www.adces.org
https://www.dexcom.com



ADCES. danatech Diabetes Technology. 2024.
Dexcom [Internet]. 2026. ; Dexcom. G7 15 Day User Guide. 2025.

G7 15 Day by Dexcom

Dexcom G7
Continuous Glucose Monitoring
★★★☆☆ 5.8K

Dexcom Clarity
Medical
★★★★½ 12K

Dexcom Follow
CGM Remote Monitoring
★½☆☆☆ 615

- Compatibility:
  - iOS (iOS 18.6.0 – 26.2)
  - Android (OS 13 – 16)





Dexcom. G7 15 Day User Guide. 2025.
Dexcom [Internet]. 2026.

Images from: iphone App store; Dexcom. G7 15 Day User Guide. 2025.

Libre Freestyle 3 Plus by Abbott

Libre Freestyle 3 Plus

- For patients ≥ 2 years for managing diabetes
- Log meals, activities, medication, notes
  - Photo capabilities with “Libre Assist”
- Provides trends, readings, history, alerts
- NO direct connection to Apple Health® or Google Health Connect™
- RCT: 332 patients ≥ 2 yrs with DMT1 or DMT2 and Freestyle 2+
  - Up to 3 Clinic visits → venous BG readings paired to CGM readings
  - Adult MARD = 8.2%
  - Pediatric 6-17 years MARD = 8.1%
  - Pediatric 2-5 years MARD 11.2%
  - 94.2%, 94.0%, 86.6% of values within 20% of comparator values



Images from:
https://www.adces.org
https://www.freestyle.abbott/us-en/products/freestyle-libre-app.html

ADCES. danatech Diabetes Technology. 2024.
FreeStyle Libre [Internet]. 2026. ; Alva S, et al. JDST. 2025.

Libre Freestyle 3 Plus by Abbott

Libre by Abbott
Continuous Glucose Monitoring
★★★★½ 80K

LibreLinkUp
Medical
★★★★★ 21K

LibreView

- Compatibility:
  - iOS (iOS 16 – 18.6)
  - Android (OS 11 – 16)
  - watchOS (10+)

- LibreLinkUp → connect with others
- LibreView → connect with HCP



FreeStyle Libre [Internet]. 2026.

Images from: iphone App store; FreeStyle Libre 3 App User's Manual

Rx CGM Comparison

	G7 15 Day	Freestyle Libre 3 Plus
Manufacturer	Dexcom	Abbott
FDA Indication	≥ 18 years	≥ 2 years
Lifespan	15 days + 12 hour grace period	15 days
Warmup Time	60 minutes	60 minutes
Glucose Range	40 - 400 mg/dL	40 - 400 mg/dL
Reporting	Sends readings every 5 min	Seconds readings every 1 min
Application Site	Back of upper arm	Back of upper arm
Customizable Alerts	Yes	Yes

ADCES. danatech Diabetes Technology [Internet]. 2024.
Dexcom. G7 15 Day User Guide. 2025.
Freestyle Libre 3. App User's Manual. 2025.

Rx CGM Comparison

	G7 15 Day	Freestyle Libre 3 Plus
App	“Dexcom G7”; “Dexcom Clarity”; “Dexcom Follow”	“Libre by Abbott”; “LibreLinkUp”
Receiver	Available; not required*	Available; not required
Pump Compatible	Yes	Yes
Water	Waterproof; Max 8 ft	Resistant; Max 3 ft x 30 mins
Insurance Coverage	Yes	Yes
HSA/FSA Eligibility	Yes	Possibly
Affordability	15 day free trial ; Coupons ; Patient Assistance Programs	15 day free trial ; Copay Card ; Veterans Program

ADCES. danatech Diabetes Technology [Internet]. 2024.
Dexcom [Internet]. 2026. ; FreeStyle Libre [Internet]. 2026.

Currently Approved OTC CGM Products

OTC CGMs: Let's Focus In

Stelo by Dexcom (March 2024)

Lingo by Libre (June 2024)

Libre Rio by Libre (June 2024)*

Stelo by Dexcom CGM

Stelo

- For patients ≥ 18 years, not on insulin
- Can be used by individuals with prediabetes or DMT2
- Not for diabetes diagnosing
- Provides trends ; “Insights”; weekly spike report
- Patient education provided in “Learn Tab”
- Connects to Apple Health®, Google Health Connect™
- RCT: Patients with DMT1/DMT2 wore CGM ~15 days
  - 4 Clinic visits → readings taken by glucose analyzer and paired to CGM data
  - Overall MARD (mean absolute relative difference)= 8.3%
  - 93.1% of iCGM values were within 20% of comparator values

Images from:
https://www.stelo.com/buy

Dexcom. Stelo User Guide. 2025.; ADCES. danatech Diabetes Technology. 2024.; FDA. 510(k) Stelo Decision Summary. 2024.

Stelo by Dexcom CGM



- Compatibility:
  - iOS (iOS 18.6 – 26.0.1)
  - Android (OS 13 – 16)

- Stelo platform based on Dexcom G7 CGM technology





Images from: iphone App store; Dexcom. Stelo User Guide. 2025.

Dexcom. Stelo User Guide. 2025.
Dexcom. Stelo by Dexcom [Internet]. 2026.

Lingo by Libre CGM

Lingo by Libre

- For patients ≥ 18 years, not on insulin
- Not for diabetes (or other) diagnosing
- Daily, weekly, monthly snapshots
- Coaching program
- Connects to Apple Health® , Google Health Connect™
- RCT: compared participants +/- a CGM
  - CGM group had better cholesterol, FBG, A1C, weight, body fat, BMI

Images from:
https://www.hellolingo.com/products

Abbott. Lingo [Internet]. 2025.
Abbott. Lingo User Guide. 2025.
ADCES. danatech Diabetes Technology. 2024.
Chekima, et al. Foods. 2022.

Lingo by Libre CGM



- Compatibility:
  - iOS (iOS 15.2 – 18.7)
  - Android (OS 12 – 16)

- Platform is based on FreeStyle Libre technology





Abbott. Lingo User Guide. 2025.

Images from: iphone App store; Lingo User Guide

Libre Rio by Libre CGM

Libre Rio

- For patients:
  - ≥ 18 years
  - With DMT2
  - Not on insulin
- Geared towards patients who use lifestyle modifications (diet/exercise) for diabetes management
- Platform is based on FreeStyle Libre technology
- Release date and cost unknown
- Lifespan of 14 days and expected to integrate to management app
- Glucose range is 40 - 400 mg/dL

Abbott. Press Release. 2024.
Hopcroft A. The diaTribe Foundation. 2024.

OTC CGMs Comparison

	Stelo	Lingo
Manufacturer	Dexcom	Abbott
FDA Indication	≥ 18 years; not on insulin	≥ 18 years; not on insulin
Lifespan	15 days	14 days
Warmup Time	30 minutes	60 minutes
Displayed Range	70 to 250 mg/dL*	55 to 200 mg/dL
Reporting	Measured every 5 min; Sent every 15 min	Bluetooth continuous streaming
Application Site	Back of upper arm	Back of upper arm
Customizable Alerts	No	No

Abbott. Lingo [Internet]. 2025.
Abbott. Lingo User Guide. 2025.
FDA. 510(k) Lingo Decision Summary. 2024.
FDA. 510(k) Stelo Decision Summary. 2024.
ADCES. danatech Diabetes Technology [Internet]. 2024.
Dexcom. Stelo User Guide. 2025.

OTC CGMs Comparison

	Stelo	Lingo
App	“Stelo by Dexcom”	“Lingo by Abbott”
Pump Compatible	No	No
Water	Waterproof; Max 8 ft x 24 hrs	Resistant; Max 3 ft x 30 mins
Insurance Coverage	No	No
HSA/FSA Eligibility	Yes	Yes
Cost	$55 / 2 week + 1 sensor $99 / 4 week + 2 sensors* $252 / 12 week + 6 sensors	$49 / 2 week + 1 sensor $89 / 4 week + 2 sensors $249 / 12 week + 6 sensors

Abbott. Lingo [Internet]. 2025.
Abbott. Lingo User Guide. 2025.
FDA. 510(k) Lingo Decision Summary. 2024.
FDA. 510(k) Stelo Decision Summary. 2024.
ADCES. danatech Diabetes Technology [Internet]. 2024.
Dexcom. Stelo User Guide. 2025.

For More Information

- There are great free resources available online for clinicians to utilize to compare, contrast, and learn about currently available CGM and sensor products.

- American Association of Clinical Endocrinology (AACE)
  - https://pro.aace.com/cgm/toolkit/cgm-device-comparison

- Danatech, powered by the Association of Diabetes Care & Education Specialists (ADCES)
  - https://www.adces.org/education/danatech/glucose-monitoring/continuous-glucose-monitors-(cgm)/view-compare-cgms

CGM Safety Concerns and Considerations

Safety Concerns with CGMs: Let's Focus In

Data Accuracy and Interpretation

Mental Health Concerns

Inappropriate Self Management

The Data: When the Data is “Wrong”

The Data: When the Data is “Wrong”

Differences between interstitial glucose and blood glucose: **Lag Time**

Glucose Stable:

CGM in equilibrium with BG

Glucose Falling:

CGM likely higher than actual BG

Glucose Rising:

CGM likely lower than actual BG

The Data: When the Data is “Wrong”

Interfering substances

Medication	Dose	Systems Affected	Effect
Acetaminophen	> 4 g/day	Dexcom G6, Dexcom G7, Stelo	Higher sensor readings than actual glucose
	Any dose	Medtronic Guardian 4	
Ascorbic Acid (Vit C)	> 500 mg/day	Freestyle Libre 2, Freestyle Libre 3	
	> 1000 mg/day	Freestyle Libre 2 plus, Freestyle Libre 3 plus, Lingo	
Hydroxyurea	Any dose	Dexcom G6, Dexcom G7, Medtronic Guardian 4, Stelo	
Mannitol (IV or as peritoneal dialysis solution)	Any dose	Senseonics Eversense 365	
Sorbitol (IV or as peritoneal dialysis solution)	Any dose	Senseonics Eversense 365	

American Diabetes Association Professional Practice Committee for Diabetes*; 7. Diabetes Technology: Standards of Care in Diabetes—2026

The Data: When the Data is “Wrong”

Compression Lows:

Pressure on the sensor + **Reduced volume of interstitial fluid from which glucose is measured** → **Can translate to less glucose and incorrect low readings**

The Data: When the Data is “Wrong”

Technology Malfunction

FDA U.S. FOOD & DRUG ADMINISTRATION

Glucose Monitor Sensor Recall: Abbott Diabetes Care Removes Certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus Sensors

This recall involves removing certain devices from where they are used or sold. *The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it. The affected products have not changed, but the “Full list of affected lots” has been modified for clarity. The recommendations for what to do with the devices below have not changed. The reason for recall has been clarified and updated with current information.*

Content current as of:
02/05/2026

Regulated Product(s)
Medical Devices

Affected Product

U.S. Food and Drug Administration. Abbott initiates medical device correction for certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus. 2026 sensors.

The Data: When the Data isn't Interpreted Correctly

https://www.questionpro.com/blog/data-interpretation/

The Data: When the Data is Interpreted Incorrectly

Understanding CGM metrics: Trend Arrows

Arrow	Interpretation
	**Glucose is rising quickly** (more than 2 mg/dL per min) * changing more than 3 mg/dL each min
	**Glucose is rising** (between 1 and 2 mg/dL per min)
	**Glucose is changing slowly** (less than 1 mg/dL per min
	**Glucose is falling** (between 1 and 2 mg/dL per min)
	**Glucose is falling quickly** (more than 2 mg/dL per min) * changing more than 3 mg/dL each min

The Data: When the Data is Interpreted Incorrectly

Understanding CGM metrics: Time in Range and Goals







https://www.managedcarecgm.com/clinical-targets-for-continuous-glucose-monitoring-data-interpretation-recommendations-from-the-international-consensus-on-time-in-range/

The Data: When the Data is Interpreted Incorrectly

Postprandial spikes and “normal” variability



Kratz M. Nourished by Science. 2024

The Mental Health Concern

https://drtrust.in/ta/blogs/life-health-drtrust/how-diabetes-impacts-mental-health-relationships-strategies-for-risk-reduction-and-minimizing-silent-struggles?srsltid=AfmBOorO3UC-9pZGcMf-AOtC3cYtLUG_hT53tt30NkiSWJDzs3U1VZ3q

The Mental Health Concern: Diabetes Distress

Ask About Diabetes Distress at Each Visit

- "What is the most difficult part of living with diabetes for you?"
- "What are your greatest concerns about your diabetes?"
- "How is your diabetes affecting other things in your life right now?"

Assess Diabetes Distress with Validated Questionnaires

- PAID (Problem Areas in Diabetes) questionnaire
- DDS-17 (Diabetes Distress Scale)

American Diabetes Association. Continuous glucose monitoring and diabetes distress. 2024

The Mental Health Concern: CGM Distress and Disordered Eating

Participants

Patients:
- 56 total pts
- No DM (46.4%)
- Prediabetes (3.6%)
- Type 2 DM (50%)
- Mean Age: 39.7

Outcomes

Statement	Results
"Seeing high glucose levels made me feel afraid about the risk of type 2 DM"	68% of participants agreed or strongly agreed with statement Correlated with a higher score on EDE-QS score *(disordered eating scale)*
"Using CGM makes me think about my blood sugar too much"	62% of participants agreed or strongly agreed with statement
"Using a CGM made me feel like I have more control over my blood sugar"	Those with depression more strongly disagreed with the statement.

Key Point

CGM has healthy lifestyle benefits but it also may contribute to distress particularly among younger and those with obesity, high agreeableness and eatings disorder symptoms.

Richardson KM et al. *Obes Res Clin Pract*. 2025

The Mental Health Concern: Alarm Fatigue

What is alarm fatigue?

- Repeated or non-actionable alerts leading to desensitization or alarm disabling

Why does it matters for safety?

- Missed hypoglycemia or hyperglycemia alerts
- Delayed response to clinically significant glucose events

What are common contributors?

- Overly tight alert thresholds
- Inappropriate action to alarms

Inappropriate Self Management

https://www.iowadiabetes.com/2022/01/03/diabetes-self-management-education-and-support-dsmes/

Inappropriate Self-Management Behaviors

- Unsupervised or unnecessary dietary or lifestyle changes based solely on CGM data
- Self-adjustment of prescription or OTC medications without guidance
- False reassurance or delayed medical evaluation due to perceived “normal” readings
- Use of OTC CGM in populations for which it was not intended (e.g., insulin users)
- Over reliance on technology

7. Diabetes Technology: Standards of Care in Diabetes—2026

Pharmacist Role in Risk Mitigation

- Educate on alarms and help prevent alarm fatigue
- Set expectations and clarify device limitations
- Identify red flags requiring further evaluation
- Educate on when CGM data should *not* solely guide self-management decisions
- Monitor for mental health concerns related to CGM use

Patient Scenario

ML (55 yo WF) Presents to her Community Pharmacy

Setting the Scene:

- ML is picking up refills of her metformin and insulin prescriptions
- You ask if she has been having any issues or concerns regarding these medications, her CGM, or diabetes
- She reveals the below symptoms and related history

Symptoms/History*:*

- She wears her Libre Freestyle 3 Plus and reports frequent hypoglycemia overnight and mid-afternoon
- She is very nervous about her CGM monitor and it working correctly
- Reports over the last month she has noticed some irritation on her skin on day 1 of wearing her sensor
- She knows her A1C readings are also above goal and she doesn't know how to better manage her diabetes

Past Medical History:

- T2DM x 12 years
- HTN x 10 years
- HLD x 10 years
- Depression x 20 years

Medications:

- ***metformin*** 1000 mg BID
- ***insulin glargine*** 24 units daily
- ***insulin lispro*** 6-10 units with meals
- ***lisinopril*** 20 mg daily
- ***atorvastatin*** 20 mg daily
- **sertraline** 50 mg daily
- **Libre 3 Plus** as directed

Labs Provided by ML:

- A1C is 8.6%

ML (55 yo WF) Presents to her Community Pharmacy

What questions do you want to ask ML?

What are Patient Safety Issues You Can Identified Relating to her CGM use?

What are Recommendations, Education, or Counseling to Provide ML?

ML (55 yo WF) Presents to her Community Pharmacy

What would change if ML was using an OTC CGM?

What are Patient Safety Issues You Can Identified Relating to her OTC CGM use?

What are Recommendations, Education, or Counseling to Provide ML?

Integrating Services

Practice Workflow Considerations

- **CGM Candidate Identification**
  - Incorporate patient screenings into care visits to identify optimal patients for CGM use
  - Consider when and how often will you evaluate this for each patient

- **Device Selection**
  - Match individual patients with the optimal device based on known features, differences, availability, and access
    - Indication for use?
    - Rx vs. OTC?
    - Does patient have insurance?
    - Individual preferences (size, water resistance, days of wear, app platform, etc…)

Practice Workflow Considerations

- **Ensure Access**
  - Can the pharmacist or provider access the app / platforms?
    - Ensure this at time of set up with patient
  - Can the patient access the app and have the ability to interpret the data provided to them

- **Patient Education**
  - Identify who is expected or responsible for providing patient education
  - Determine if the patient has received the appropriate level of education
  - Create education “checklists” to ensure that all key topics are covered
    - Ex: How to set up apps, alarms, set expectations about data delay/troubleshooting
  - Potentially train interns/technician on devices as part of your workflow

Practice Workflow Considerations

- **Follow up and Monitoring**
  - Establish cadence for CGM review:
  - Initial follow-up (1–2 weeks after start)
  - Ongoing (monthly or quarterly)

- **Documentation and Billing**
  - Build templates for CGM Patient Data Review
  - Document Time spent reviewing CGM reports
  - Clinical recommendations
  - CGM teaching and interpretation codes (95249, 95251, incident-to billing

Practice Workflow Considerations

- Application strategies may vary depending on your clinical practice setting
  - **Community Pharmacy**
    - Ensure that standard procedure at a dispensing of CGM devices includes opportunities to sit down and provide detailed patient education
  - **Ambulatory Care Clinic Setting**
    - Sufficient appointment time dedicated to reviewing the CGM device, smartphone applications or readers, and clinic platforms
  - **Inpatient Setting**
    - Less likely to see “new” CGM starts, but can determine patient knowledge and comfortability at discharge and either provide counseling or set up a follow up appointment with patients PCP

Conclusions

- Advancement in CGM technology has grown exponentially since the 1970s, and we will continue to see innovation in this area as use of **CGMs becomes the standard of care**.

- CGMs are crucial diabetes technology that have **significantly improved patient management of diabetes** as well as increased understanding of of how diet and exercise can impact glucose levels for those without diabetes.

- Although CGMs bring numerous benefits, they are not without potential **patient safety risks** if sufficient education is not provided.

- Healthcare professionals, including **pharmacists** are crucial players in ensuring that patients receive sufficient demonstration, education, monitoring, and follow-up regarding CGM use.

References

1. Bender C, Vestergaard P, Cichosz SL. The history, evolution and future of continuous glucose monitoring (CGM). Diabetology. 2025; 6(3):17. https://doi.org/10.3390/diabetology6030017
2. Jen. ConnectedinMotion: History of the Dexcom CGM: revolutionizing glucose management [Internet]. Toronto (Canada): The Experiential Diabetes Education Group; 2023 Oct 30 [cited 2026 Feb 12]. Available from: https://www.connectedinmotion.ca/blog/history-of-the-dexcom-cgm/
3. Afon Technology: A brief history of diabetes technology [Internet]. Caldicot (Wales): Afon Technology; 2024 [cuted 2026 Feb 12]. Available from: https://afontechnology.com/2023/07/07/a-brief-history-of-diabetes-technology/
4. Brown A. diaTribeLearn: FDA approves pediatric use of Dexcom's G4 Platinum CGM [Internet]. San Francisco (CA): The diaTribe Foundation; 2021 [reviewed 2021 Aug 14; cited 2026 Feb 12]. Available from: https://diatribe.org/diabetes-technology/fda-approves-pediatric-use-dexcoms-g4-platinum-cgm
5. AJMC Staff. AJMC: Dexcom G5 mobile CGM system approved by FDA [Press Release]. Cranberry (NJ): 2015 Aug 24 [cited 2026 Feb 12]. Available from: https://www.ajmc.com/view/dexcom-g5-mobile-cgm-system-approved-by-fda#:~:text=Dexcom%20G5%20Mobile%20CGM%20System,cost%20or%20no%2Dcost%20upgrades
6. Prahalad P, Ding VY, Zaharieva DP, et al. Teamwork, targets, technology, and tight control in newly diagnosed type 1 diabetes: the Pilot 4T Study. J Clin Endocrinol Metab 2022;107:998–1008
7. Tanenbaum ML, Zaharieva DP, Addala A, et al. "I was ready for it at the beginning": parent experiences with early introduction of continuous glucose monitoring following their child's type 1 diabetes diagnosis. Diabet Med 2021;38:e14567
8. Addala A, Maahs DM, Scheinker D, Chertow S, Leverenz B, Prahalad P. Uninterrupted continuous glucose monitoring access is associated with a decrease in HbA1c in youth with type 1 diabetes and public insurance. Pediatr Diabetes 2020;21:1301–1309
9. Aleppo G, Beck RW, Bailey R, et al.; Type 2 Diabetes Basal Insulin Users: The Mobile Study (MOBILE) Study Group. The effect of discontinuing continuous glucose monitoring in adults with type 2 diabetes treated with basal insulin. Diabetes Care 2021;44:2729–2737
10. Aronson R, Abitbol A, Bajaj HS, et al. Continuous glucose monitoring in noninsulin-treated type 2 diabetes: a critical review of reported trials with an updated systematic review and meta-analysis of randomised controlled trials. Diabetes Obes Metab 2025;27:6220–6242
11. Richardson KM, Jospe MR, Somerville J, Felrice J, Schembre SM. Understanding the benefits and psychological burdens of using continuous glucose monitoring for lifestyle change: a mixed-methods cross-sectional study. Obes Res Clin Pract. 2025;19(5):417-426. doi:10.1016/j.orcp.2025.10.003
12. Vakharia M, Lyons SK, Buckingham D, et al. Initiating insulin pumps in youth with new-onset type 1 diabetes: a quality improvement initiative. Pediatr Qual Saf 2025;10:e803
13. American Diabetes Association. Continuous glucose monitoring and diabetes distress. Published 2024. March 21, 2026. https://professional.diabetes.org/sites/dpro/files/2024-03/CGMandDiabetesDistress.pdf
14. Abbott. No more routine finger sticks for Americans with diabetes: Abbott's FreeStyle Libre approved in the U.S. [Press release]. Abbott Park (IL): PRNewswire Abbott; 2017 Sept 17 [cited 2026 Feb 12]. Available from: https://abbott.mediaroom.com/2017-09-27-No-More-Routine-Finger-Sticks-1-for-Americans-with-Diabetes-Abbott-s-FreeStyle-R-Libre-Approved-in-the-U-S#:~:text=Even%20with%20current%20CGM%20devices,BETTER%20IDENTIFY%20TRENDS%20AND%20PATTERNS

References

15. FDA. FDA News Release: FDA approves first continuous glucose monitoring system with a fully implantable glucose sensor and compatible mobile app for adults with diabetes [Press Release]. Silver Spring (MD): 2018 Jun 21 [cited 2026 Feb 12]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-continuous-glucose-monitoring-system-fully-implantable-glucose-sensor-and
16. Soni A, Wright N, Agwu JC, Drew J, Kershaw M, Moudiotis C, et al. Arch Dis Child Educ Pract Ed. 2022;107:188–193. doi:10.1136/archdischild- 2020- 321190
17. Dexcom. Dexcom [Internet]. Dexcom, Inc; 2026 [cited 2026 Feb 10]. Available from: https://www.dexcom.com/
18. Dexcom. Dexcom G7 15 Day User Guide [Internet]. San Diego (CA): Dexcom, Inc; 2025 May [cited 2026 Feb 10]. Available from: https://dexcompdf.s3.us-west-2.amazonaws.com/en-us/G7-15-CGM-Users-Guide.pdf
19. Freestyle Libre. Abbott [Internet]. Abbott; 2026 [cited 2026 Feb 11]. Available from: https://www.freestyle.abbott/us-en/home.html
20. Freestyle Libre 3 App User Manual [Internet]. Alameda (CA): Abbott; 2025 [updated 2025 October; cited 2026 Feb 11]. Available from: https://freestyleserver.com/distribution/fxaa20.aspx?product=NS_fsl3usermanual&version=latest&os=all&region=us&language=xx_yy
21. Alva S, Bhargava A, Bode B, Brazg R, Castorino K, Kipnes M, et al. Accuracy of a 15-day factory-calibrated continuous glucose monitoring system with improved sensor design. JDST. 2025;0(0). doi: 10.1177/19322968251329364
22. Dexcom. Stelo User Guide [Internet]. Dexcom, Inc; 2025 [updated 2025 Mar; cited 2026 Feb 2]. Available from: https://dexcompdf.s3.us-west-2.amazonaws.com/Stelo/AW-1000421-10+Stelo+User+Guide.pdf
23. Dexcom. Stelo by Dexcom [Internet]. Stelo, Inc.; 2026 [cited 2026 Feb 3]. Available from: www.stelo.com
24. U.S. Food and Drug Administration (FDA). Stelo 510(k) Substantial Equivalence Determination Decision Summary [Internet]. Silver Spring (MD): Food and Drug Administration; 2024 [cited 2026 Feb 3]. Available from: https://www.accessdata.fda.gov/cdrh_docs/reviews/K234070.pdf
25. Abbott. Lingo User Guide [Internet]. Abbott; 2025 [cited 2026 Jan 29]. Available from: https://www.hellolingo.com/s/lingo101-guide.pdf
26. Association of Diabetes Care & Education Specialists (ADCES): danatech Diabetes Technology [Internet]. Find & Compare Continuous Glucose Monitors. Association of Diabetes Care & Education Specialists; 2024 [updated 2026; cited 2025 Jan 29]. Available from: https://www.adces.org/education/danatech/glucose-monitoring/continuous-glucose-monitors-(cgm)/view-compare-cgms
27. American Diabetes Association Professional Practice Committee for Diabetes*; 7. Diabetes Technology: Standards of Care in Diabetes—2026. *Diabetes Care* 1 January 2026; 49 (Supplement_1): S150–S165. https://doi.org/10.2337/dc26-S007
28. U.S. Food and Drug Administration (FDA). Lingo 510(k) Substantial Equivalence Determination Decision Summary [Internet]. Silver Spring (MD): Food and Drug Administration; 2024 [cited 2026 jan 29]. Available from: https://www.accessdata.fda.gov/cdrh_docs/reviews/K233655.pdf
29. Chekima K, Noor MI, Ooi YBH, Yan SW, Jaweed M, Chekima B. Utilising a real-time continuous glucose monitor as part of a low glycaemic index and load diet and determining its effect on improving dietary intake, body composition and metabolic parameters of overweight and obese young adults: a randomised controlled trial. Foods. 2022;11(12):1754. doi:10.3390/foods11121754. https://pubmed.ncbi.nlm.nih.gov/35741952/

References

30. Abbott. Abbott Receives U.S. FDA Clearance for Two New Over-the-Counter Continuous Glucose Monitoring Systems [Press release]. Abbott Park (IL): PRNewswire Abbott; 2024 June 10 [cited 2026 Feb 3]. Available from: https://abbott.mediaroom.com/2024-06-10-Abbott-Receives-U-S-FDA-Clearance-for-Two-New-Over-the-Counter-Continuous-Glucose-Monitoring-Systems#:~:text=Libre%20Rio%20will%20be%20Abbott's,low%20or%20high%20glucose%20events.
31. Hopcroft A. FDA Clears Two New Abbott Over-the-Counter CGMs [Internet]. San Francisco (CA): The diaTribe Foundation; 2024 September 9 [cited 2026 Feb 3]. Available from: https://diatribe.org/diabetes-technology/fda-clears-two-new-abbott-over-counter-cgms
32. Dexcom [Internet]. Will the Dexcom G6 discontinuation impact Dexcom G6 Pro? Dexcom; 2026 [cited 2026 Feb 4]. Available from: https://provider.dexcom.com/will-dexcom-g6-discontinuation-impact-dexcom-g6-pro
33. American Diabetes Association. Continuous glucose monitoring and diabetes distress. Published 2024. Accessed March 21, 2026. https://professional.diabetes.org/sites/dpro/files/2024-03/CGMandDiabetesDistress.pdf
34. Heltzel P. 7 common CGM hang-ups (and how to get around them). diaTribe Foundation. Published August 26, 2024. Accessed March 21, 2026. https://diatribe.org/diabetes-technology/7-common-cgm-hang-ups-and-how-get-around-them
35. U.S. Food and Drug Administration. Abbott initiates medical device correction for certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors. Published January 15, 2026. Accessed March 21, 2026. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/abbott-initiates-medical-device-correction-certain-freestyle-librer-3-and-freestyle-libre-3-plus
36. Kratz M. How to interpret your CGM data. Nourished by Science. Published August 16, 2024. Accessed March 21, 2026. https://nourishedbyscience.com/how-to-interpret-your-cgm-data/
37. Richardson KM, Jospe MR, Somerville J, Felrice J, Schembre SM. Understanding the benefits and psychological burdens of using continuous glucose monitoring for lifestyle change: A mixed-methods cross-sectional study. *Obes Res Clin Pract*. 2025;19(5):417-426. doi:10.1016/j.orcp.2025.10.003

Safe Starts with Sensors: Pharmacists' Role in CGM Use

Emily Eddy ***PharmD, CDCES, BC-ADM, BCACP***
Associate Professor of Pharmacy Practice
Ohio Northern University
e-eddy.1@onu.edu

Brittany Long ***PharmD, BCACP, CTTS***
Associate Professor of Pharmacy Practice
Ohio Northern University
b-brock@onu.edu

Pharmacy Forward: Advancing Practice for a Healthier Tomorrow!

OPA Annual Conference & Trade Show April 9-11, 2026

OHIO PHARMACISTS ASSOCIATION